130,200 Shares of CareDx, Inc. $CDNA Purchased by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC bought a new position in CareDx, Inc. (NASDAQ:CDNA) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 130,200 shares of the company’s stock, valued at approximately $8,463,000. CareDx makes up approximately 2.3% of Lisanti Capital Growth LLC’s investment portfolio, making the stock its 5th biggest position.

Other hedge funds have also modified their holdings of the company. Allspring Global Investments Holdings LLC grew its position in shares of CareDx by 4.4% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 23,000 shares of the company’s stock worth $1,523,000 after buying an additional 961 shares during the last quarter. Ethic Inc. purchased a new stake in CareDx during the third quarter valued at approximately $379,000. Alps Advisors Inc. purchased a new stake in CareDx during the third quarter valued at approximately $720,000. Calamos Advisors LLC purchased a new stake in CareDx during the third quarter valued at approximately $225,000. Finally, Profund Advisors LLC boosted its stake in CareDx by 23.7% in the third quarter. Profund Advisors LLC now owns 20,441 shares of the company’s stock valued at $1,329,000 after acquiring an additional 3,923 shares in the last quarter.

Insider Transactions at CareDx

In other CareDx news, CFO Keith Kennedy sold 61,961 shares of the firm’s stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $77.82, for a total value of $4,821,805.02. Following the completion of the transaction, the chief financial officer owned 199,147 shares of the company’s stock, valued at approximately $15,497,619.54. This trade represents a 23.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 2.40% of the company’s stock.

CareDx Stock Up 0.5%

CDNA opened at $81.17 on Thursday. The company has a market cap of $4.26 billion, a P/E ratio of 33.96 and a beta of 2.51. The firm’s 50-day moving average price is $65.18 and its 200-day moving average price is $36.12. CareDx, Inc. has a 52-week low of $15.15 and a 52-week high of $90.87.

CareDx (NASDAQ:CDNA) last released its earnings results on Thursday, October 29th. The company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.25 by $0.45. The company had revenue of $139.36 million during the quarter, compared to analysts’ expectations of $121.96 million. CareDx had a net margin of 25.86% and a return on equity of 9.74%. CareDx’s revenue for the quarter was up 39.3% on a year-over-year basis. During the same period last year, the business earned $0.03 EPS. On average, research analysts anticipate that CareDx, Inc. will post 0.99 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on CDNA shares. HC Wainwright reaffirmed a “neutral” rating and issued a $46.00 price target on shares of CareDx in a report on Friday, July 31st. Wall Street Zen downgraded CareDx from a “strong-buy” rating to a “buy” rating in a research report on Saturday, October 31st. Craig Hallum upgraded CareDx from a “hold” rating to a “buy” rating and set a $64.00 price objective for the company in a report on Monday, August 3rd. Piper Sandler initiated coverage on CareDx in a research report on Wednesday. They issued an “overweight” rating and a $100.00 price objective for the company. Finally, William Blair upgraded CareDx to a “hold” rating in a research note on Thursday, July 16th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $70.33.

About CareDx

CareDx, Inc. is a precision medicine company focused on organ transplantation. It develops and provides diagnostic tests and related services to help clinicians assess transplant recipients and monitor their health over time. Its offerings include AlloSure, a donor-derived cell-free DNA test used to help monitor for organ rejection, and AlloMap, a gene-expression test used in heart transplant care. CareDx also provides histocompatibility testing, clinical tools, and services designed to support patients and transplant care teams.